Literature DB >> 7552492

An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently Tat-transfected cells and required for optimal HIV-1 LTR transactivating activity.

G Zauli1, M La Placa, M Vignoli, M C Re, D Gibellini, G Furlini, D Milani, M Marchisio, M Mazzoni, S Capitani.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) transactivating Tat protein is pivotal to virus replication. Tat's potential effects on HIV-1 pathogenesis, however, go well beyond its role in the virus's life cycle. Current data indicate that biologically active Tat is released from HIV-1-infected cells and readily endocytosed and targeted to the nucleus of nearby, or perhaps distant, cells, where it may exert a series of pleiotropic effects. This paracrine action has been extensively investigated, and depending on the amounts of exogenously added Tat, its effects may extend from the suppression of immunocompetent cells to transactivation of heterologous genes to the promotion of growth of Kaposi's sarcoma spindle cells. We have already observed that various cell lines, either permanently transfected with an expressive HIV-1 tat gene construct or cultured in the presence of exogenously added Tat protein, are protected from programmed cell death after serum withdrawal or other apoptotic stimuli. The present article shows that various types (lymphoblastoid, epithelial, neuronal) of permanently tat-transfected cell lines actively release fully bioactive Tat protein. The addition of anti-Tat antibody to the culture medium completely abolishes their increased survival/proliferation capacity in serum-free culture. In these conditions, therefore, the enhanced survival/proliferation potential of permanently tat-transfected cells seems entirely dependent on a Tat-protein autocrine loop. The finding that anti-Tat antibody, added to culture medium, exerts a negative influence on the expression of a Tat-responsive HIV-1 long terminal repeat chloramphenicol-acetyltransferase construct, transiently transfected into permanently tat-transfected cells, suggests that the Tat autocrine loop may also be required for optimal HIV-1 long terminal repeat transactivation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7552492

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  19 in total

1.  Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.

Authors:  R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

2.  Selective up-regulation of functional CXCR4 expression in erythroid cells by HIV-1 Tat protein.

Authors:  D Gibellini; M C Re; F Vitone; N Rizzo; C Maldini; M La Placa; G Zauli
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

3.  Mechanism of HIV-1-TAT induction of interleukin-1beta from human monocytes: Involvement of the phospholipase C/protein kinase C signaling cascade.

Authors:  Yongbo Yang; Jianguo Wu; Yuanan Lu
Journal:  J Med Virol       Date:  2010-05       Impact factor: 2.327

4.  Extracellular HIV Tat and Tat cysteine rich peptide increase CCR5 expression in monocytes.

Authors:  Lin Zheng; Yi-da Yang; Guo-cai Lu; Maria S Salvato
Journal:  J Zhejiang Univ Sci B       Date:  2005-07       Impact factor: 3.066

Review 5.  Doxycycline-inducible and astrocyte-specific HIV-1 Tat transgenic mice (iTat) as an HIV/neuroAIDS model.

Authors:  Dianne Langford; Byung Oh Kim; Wei Zou; Yan Fan; Pejman Rahimain; Ying Liu; Johnny J He
Journal:  J Neurovirol       Date:  2017-11-15       Impact factor: 2.643

6.  Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline.

Authors:  Byung Oh Kim; Ying Liu; Yiwen Ruan; Zao C Xu; Laurel Schantz; Johnny J He
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

7.  Exosome-associated release, uptake, and neurotoxicity of HIV-1 Tat protein.

Authors:  Pejman Rahimian; Johnny J He
Journal:  J Neurovirol       Date:  2016-05-12       Impact factor: 2.643

8.  A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.

Authors:  S M Agwale; M T Shata; M S Reitz; V S Kalyanaraman; R C Gallo; M Popovic; D M Hone
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-02       Impact factor: 11.205

9.  Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism.

Authors:  Yida Yang; Ilia Tikhonov; Tracy J Ruckwardt; Mahmoud Djavani; Juan Carlos Zapata; C David Pauza; Maria S Salvato
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 tat-mediated cytotoxicity of human brain microvascular endothelial cells.

Authors:  Naveed Ahmed Khan; Francescopaolo Di Cello; Avi Nath; Kwang Sik Kim
Journal:  J Neurovirol       Date:  2003-12       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.